Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer

被引：1

作者：

Wyrwicz, L. ^{[1
]}

Oh, D. ^{[2
]}

Weber, P. ^{[3
]}

Bai, Y. ^{[4
]}

Ryu, M. ^{[5
]}

Lee, J. ^{[6
]}

Rivera, F. ^{[7
]}

Alves, G. Vasconcelos ^{[8
]}

Garrido, M. ^{[9
]}

Shiu, K. ^{[10
]}

Fernandez, M. Gonzalez ^{[11
]}

Li, J. ^{[12
]}

Lowery, M. ^{[13
]}

Cil, T. ^{[14
]}

Cruz, F. ^{[15
]}

Qin, S. ^{[16
]}

Yin, L. ^{[17
]}

Bordia, S. ^{[17
]}

Bhagia, P. ^{[17
]}

Rha, S. ^{[18
]}

机构：

[1] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[2] Seoul Natl Univ, Coll Med, Seoul, South Korea

[3] Univ La Frontera, James Lind Canc Res Ctr, Temuco, Chile

[4] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[5] Univ Ulsan, Asan Med Ctr, Coll Med, Songpa Gu, Seoul, South Korea

[6] Samsung Med Ctr, Seoul, South Korea

[7] Univ Hosp Marques Valdecilla, IDIVAL, Santander, Spain

[8] Hosp Nossa Senhora Coinceicao, Porto Alegre, RS, Brazil

[9] Pontificia Univ Catolica Chile, Santiago, Chile

[10] Univ Coll London NHS Fdn Trust, London, England

[11] IMAT Oncomed, Monteria, Colombia

[12] Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China

[13] Trin St James Canc Inst, Dublin, Ireland

[14] Hlth & Sci Univ, Adana City Hosp, Adana, Turkiye

[15] Nucleo Pesquisa Ensino, Rede Sao Camilo, Sao Paulo, Brazil

[16] Gen Hosp Eastern Theater PLA, Canc Ctr, Nanjing, Peoples R China

[17] Merck Co Inc, Rahway, NJ USA

[18] Yonsei Univ, Yonsei Univ Hlth Syst, Songdang Inst Canc Res, Yonsei Canc Ctr,Coll Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-3

引用

页码：S181 / S181

页数：1

共 50 条

[41] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
Chung, H.
Bang, Y.
Fuchs, C.
Qin, S.
Satoh, T.
Shitara, K.
Tabernero, J.
Van Cutsem, E.
Cao, Z.
Chen, X.
Kang, S.
Shih, C.
Janjigian, Y.
ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
[42] Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.
Rha, Sun Young
Revil, Cedric
Valderrama, Adriana
Wang, Liya
Andre, Manon
McCarthy, Grant
Young, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 354 - 354
[43] Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Shitara, K.
Rha, S. Y.
Wyrwicz, L. S.
Oshima, T.
Karaseva, N.
Osipov, M.
Yasui, H.
Yabusaki, H.
Afanasyev, S.
Park, Y-K.
Al-Batran, S-E.
Yoshikawa, T.
Weber, P. E. Yanez
Di Bartolomeo, M.
Lonardi, S.
Fang, X.
Shih, C-S.
Bhagia, P.
Bang, Y-J.
ANNALS OF ONCOLOGY, 2024, 35 : S213 - S213
[44] Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase III trial
Randon, G.
Nappo, F.
Fassan, M.
Tamberi, S.
Giommoni, E.
Di Donato, S.
Fornaro, L.
Brunetti, O.
De Vita, F.
Frassineti, G. L.
Chini, C.
Spallanzani, A.
Bethaz, V.
Strippoli, A.
Latiano, T. P.
Cardellino, G.
Ceccon, C.
Palermo, F.
Di Bartolomeo, M.
Pietrantonio, F.
ANNALS OF ONCOLOGY, 2024, 35 : S214 - S214
[45] A phase 3 study of chemotherapy 1 pembrolizumab vs chemotherapy 1 placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585-Trial in progress
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Ohtsu, A.
Tabernero, J.
Ilson, D.
Hyung, W.
Strong, V.
Goetze, T.
Yoshikawa, T.
Tang, L.
Hwang, P.
Shitara, K.
ANNALS OF ONCOLOGY, 2018, 29
[46] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
Janjigian, Y. Y.
Kawazoe, A.
Bai, Y.
Xu, J.
Lonardi, S.
Metges, J-P.
Weber, P. E. Yanez
Wyrwicz, L. S.
Shen, L.
Ostapenko, Y. V.
Bilici, M.
Chung, H. C.
Shitara, K.
Qin, S.
Van Cutsem, E.
Tabernero, J.
Li, K.
Shih, C-S.
Bhagia, P.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S851 - S852
[47] A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Li, Z.
Ji, J.
Bu, Z.
Wang, Y.
Wu, Z.
Nie, P.
Li, W-L.
Li, C.
You, J.
Hu, W.
Zhang, Y.
Chen, L.
Zhao, P.
Li, G.
Li, Y.
Zhuang, J.
Shen, J.
Feng, D.
Fang, J.
ANNALS OF ONCOLOGY, 2024, 35 : S911 - S911
[48] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
Morimoto, Kosuke
Moriwaki, Kensuke
Shimozuma, Kojiro
Nakayama, Takeo
JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
[49] KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
Wainberg, Z. A.
Jalal, S.
Muro, K.
Yoon, H. H.
Garrido, M.
Golan, T.
Doi, T.
Catenacci, D. V.
Geva, R.
Ku, G.
Bleeker, J.
Bang, Y-J.
Hara, H.
Chung, H. C.
Savage, M.
Wang, J.
Koshiji, M.
Dalal, R.
Fuchs, C. S.
ANNALS OF ONCOLOGY, 2017, 28
[50] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
Kosuke Morimoto
Kensuke Moriwaki
Kojiro Shimozuma
Takeo Nakayama
Journal of Gastroenterology, 2023, 58 : 1188 - 1197

← 1 2 3 4 5 →